Vumerity Linked to Better Quality of Life Than Tecfidera in RRMS Trial

Vumerity Linked to Better Quality of Life Than Tecfidera in RRMS Trial

291676

Vumerity Linked to Better Quality of Life Than Tecfidera in RRMS Trial

Vumerity (diroximel fumarate) is easier on the gastrointestinal tract than Tecfidera (dimethyl fumarate), and this translates into better quality of life for patients with relapsing-remitting multiple sclerosis (RRMS), a new analysis of EVOLVE-MS-2 trial data has found. The study, “Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study,” was published in the journal Therapeutic Advances…

You must be logged in to read/download the full post.